Bangalore, India — 12/21/2017 — Angina is the medical term used for describing the chest pain or discomfort that an individual can experience when the heart does not receive an adequate supply of oxygen-rich blood. This can occur when the arteries supplying blood flow to the heart muscle become partially blocked or narrowed by the accumulation of fatty deposits known as plaque. This condition, where plaque progressively builds up in the interior walls of the arteries, resulting in reduced blood flow to the myocardium, ischemia and angina, is known as coronary atherosclerosis.
The primary therapeutic options for treatment of coronary artery disease are drug therapy, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). However, many patients with severe angina experience inadequate response to pharmacological approaches and require surgical treatment such as PCI with or without stenting, or CABG.
Many patients with chronic, severe angina are not candidates for PCI or CABG because of a variety of reasons including failed prior procedures, diffuse coronary artery disease, distal stenosis or extremely small coronary arteries. These patients represent the primary target population for treatment with TMR.
Transmyocardial revascularization (TMR) is a surgically performed laser-based heart treatment procedure in which transmural channels are made in the heart muscle. Many scientific experts believe that these procedures encourage new vessel formation, also known as angiogenesis. TMR therapy is approved for patients suffering from chronic or severe angina. The American Heart Association (AHA) estimates that approximately 9.8 million Americans experience angina symptoms.
Spanning over 390 pages “US Market Report for Transmyocardial Revascularization Devices 2018 – MedCore” report covers Executive Summary, Competitive Analysis, Market Trends, Market Developments, Markets Included, Research Methodology, Disease Overview, Product Portfolio, Transmyocardial Revascularization Device Market, Appendix. This report Covered Companies – Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.
For more information Visit at: https://www.drugpipeline.net/idata-research/us-market-report-transmyocardial-revascularization-devices-2018-medcore
Find all Pharma and Healthcare Reports at – http://www.drugpipeline.net/catalog/pharma-healthcare
US Market Report for Remote Hemodynamic Monitoring Systems 2018 – MedCore – Visit at – https://www.drugpipeline.net/idata-research/us-market-report-remote-hemodynamic-monitoring-systems-2018-medcore
US Market Report for Patent Foramen Ovale Devices 2018 – MedCore – Visit at – https://www.drugpipeline.net/idata-research/us-market-report-patent-foramen-ovale-devices-2018-medcore
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.